Amyloid beta 1-43 as a potential biomarker for the detection of early Alzheimer’s disease
Has parts
Paper 1: Lauridsen, Camilla; Sando, Sigrid Botne; Shabnam, Adiba; Møller, Ina; Berge, Guro; Grøntvedt, Gøril Rolfseng; Bakken, Inger Johanne; Salvesen, Øyvind; Bråthen, Geir; White, Linda. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. Frontiers in Aging Neuroscience 2016 ;Volum 8 https://doi.org/10.3389/fnagi.2016.00030 This is an open-access article Attribution 4.0 International (CC BY 4.0)Paper 2: Lauridsen C, Sando SB, Møller I, Berge G, Pomary PK, Grøntvedt GR, Salvesen Ø, Bråthen G and White LR (2017) Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42. Frontiers in Aging Neuroscience 28 June 2017 |https://doi.org/10.3389/fnagi.2017.00210 This is an open-access article Attribution 4.0 International (CC BY 4.0)
Paper 3: Almdahl, Ina; Lauridsen, Camilla; Selnes, Per; Kalheim, Lisa Flem; Coello, Christopher; Gajdzik, Beata; Møller, Ina; Wettergreen, Marianne; Grambaite, Ramune; Bjørnerud, Atle; Bråthen, Geir; Sando, Sigrid Botne; White, Linda; Fladby, Tormod. Cerebrospinal fluid levels of amyloid beta 1-43 mirror 1-42 in relation to imaging biomarkers of Alzheimer's disease. Frontiers in Aging Neuroscience 2017 ;Volum 9:9. s. 1-13 https://doi.org/10.3389/fnagi.2017.00009 This is an open-access article Attribution 4.0 International (CC BY 4.0)